Low incidence rate of respiratory and viral infections over 5 years of treatment with tildrakizumab in patients with moderate‐to‐severe psoriasis: pooled analysis from reSURFACE 1 and reSURFACE 2 phase 3 trials

Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China

(2020) Chaolin Huang et al.   LANCET

TH17 responses in cytokine storm of COVID-19: An emerging target of JAK2 inhibitor Fedratinib

(2020) Dandan Wu et al.   JOURNAL OF MICROBIOLOGY IMMUNOLOGY AND INFECTION

The risk of respiratory tract infections and symptoms in psoriasis patients treated with IL-17-pathway inhibiting biologics: A meta-estimate of pivotal trials relevant to decision-making during the COVID-19 pandemic

(2020) Marilyn T. Wan et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

The Risk of Respiratory Tract Infections in Psoriasis Patients Treated With IL-23-pathway Inhibiting Biologics: A Meta-Estimate of Pivotal Trials Relevant to Decision-Making During the COVID-19 Pandemic

(2020) Maha N. Syed et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Factors associated with adverse COVID-19 outcomes in patients with psoriasis – insights from a global registry-based study

(2020) Satveer K. Mahil et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Characteristic of chronic plaque psoriasis patients treated with biologics in Italy during the COVID-19 Pandemic: Risk analysis from the PSO-BIO-COVID observational study

(2020) Marina Talamonti et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Longitudinal active sampling for respiratory viral infections across age groups

(2019) Marta Galanti et al.   Influenza and Other Respiratory Viruses

Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials

(2017) Kristian Reich et al.   LANCET